BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) reflects an aberrant immune response that can develop in human immunodeficiency virus-infected patients initiating antiretroviral therapy (ART). Its pathogenesis remains unclear. METHODS: We performed a nested case-control study using specimens from ACTG A5164. We compared plasma biomarkers and T-cell subsets in 19 IRIS and 39 control participants at study entry, ART initiation, and IRIS and used conditional logistic regression to develop IRIS predictive models. We evaluated the effect of corticosteroids on biomarker levels. RESULTS: Eleven and 8 participants developed paradoxical and unmasking IRIS, respectively, none while still receiving corticosteroids. Compared to controls, cases displayed elevations at study entry in interleukin (IL) 8, T-helper (Th) 1 (IL-2, interferon [IFN]-γ, tumor necrosis factor [TNF]) and Th17 (IL-17) cytokine levels that persisted through ART initiation and IRIS. In logistic regression, baseline higher IFN-γ and TNF were strong predictors of IRIS. Participants who received corticosteroids and later developed IRIS had marked increases in IL-6, IL-8, and IFN-γ at the time of IRIS. T-cell activation markers did not differ in cases and controls prior to ART but were increased in cases at the time of IRIS. CONCLUSIONS: Increased IL-8, Th1, and Th17 cytokine levels in IRIS patients precede ART initiation and could help identify patient populations at higher risk for IRIS.
BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) reflects an aberrant immune response that can develop in human immunodeficiency virus-infectedpatients initiating antiretroviral therapy (ART). Its pathogenesis remains unclear. METHODS: We performed a nested case-control study using specimens from ACTG A5164. We compared plasma biomarkers and T-cell subsets in 19 IRIS and 39 control participants at study entry, ART initiation, and IRIS and used conditional logistic regression to develop IRIS predictive models. We evaluated the effect of corticosteroids on biomarker levels. RESULTS: Eleven and 8 participants developed paradoxical and unmasking IRIS, respectively, none while still receiving corticosteroids. Compared to controls, cases displayed elevations at study entry in interleukin (IL) 8, T-helper (Th) 1 (IL-2, interferon [IFN]-γ, tumor necrosis factor [TNF]) and Th17 (IL-17) cytokine levels that persisted through ART initiation and IRIS. In logistic regression, baseline higher IFN-γ and TNF were strong predictors of IRIS. Participants who received corticosteroids and later developed IRIS had marked increases in IL-6, IL-8, and IFN-γ at the time of IRIS. T-cell activation markers did not differ in cases and controls prior to ART but were increased in cases at the time of IRIS. CONCLUSIONS: Increased IL-8, Th1, and Th17 cytokine levels in IRIS patients precede ART initiation and could help identify patient populations at higher risk for IRIS.
Authors: N A Foudraine; E Hovenkamp; D W Notermans; P L Meenhorst; M R Klein; J M Lange; F Miedema; P Reiss Journal: AIDS Date: 1999-02-04 Impact factor: 4.177
Authors: E M Race; J Adelson-Mitty; G R Kriegel; T F Barlam; K A Reimann; N L Letvin; A J Japour Journal: Lancet Date: 1998-01-24 Impact factor: 79.321
Authors: Graeme Meintjes; Keira H Skolimowska; Katalin A Wilkinson; Kerryn Matthews; Rebecca Tadokera; Anali Conesa-Botella; Ronnett Seldon; Molebogeng X Rangaka; Kevin Rebe; Dominique J Pepper; Chelsea Morroni; Robert Colebunders; Gary Maartens; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2012-06-14 Impact factor: 21.405
Authors: Alessandro Cozzi-Lepri; Martyn A French; John Baxter; Pablo Okhuysen; Montserrat Plana; Jacqueline Neuhaus; Alan Landay Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Tory P Johnson; Karan Patel; Kory R Johnson; Dragan Maric; Peter A Calabresi; Rodrigo Hasbun; Avindra Nath Journal: Proc Natl Acad Sci U S A Date: 2013-07-29 Impact factor: 11.205
Authors: Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson Journal: Lancet Infect Dis Date: 2015-02-09 Impact factor: 25.071
Authors: Philip M Grant; Lauren Komarow; Alejandro Sanchez; Fred R Sattler; David M Asmuth; Richard B Pollard; Andrew R Zolopa Journal: HIV Clin Trials Date: 2014 Jul-Aug
Authors: Denise C Hsu; Kimberly F Breglio; Luxin Pei; Chun-Shu Wong; Bruno B Andrade; Virginia Sheikh; Margery Smelkinson; Constantinos Petrovas; Adam Rupert; Leonardo Gil-Santana; Adrian Zelazny; Steven M Holland; Kenneth Olivier; Daniel Barber; Irini Sereti Journal: Clin Infect Dis Date: 2018-07-18 Impact factor: 9.079
Authors: Juan G Sierra-Madero; Susan Ellenberg; Mohammed S Rassool; Ann Tierney; Pablo F Belaunzarán-Zamudio; Alondra López-Martínez; Alicia Piñeirúa-Menéndez; Luis J Montaner; Livio Azzoni; César Rivera Benítez; Irini Sereti; Jaime Andrade-Villanueva; Juan L Mosqueda-Gómez; Benigno Rodriguez; Ian Sanne; Michael M Lederman Journal: Lancet HIV Date: 2014-11-01 Impact factor: 12.767